DANIEL NAVARRO: Open Payments
NPI 1699033092 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,422 in 11 payments from 9 companies in 2025. Trend: 2023 $177 · 2024 $484 · 2025 $1,422
Food & beverage: $1,422
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $265 |
| Otsuka America Pharmaceutical, Inc. | 2 | $240 |
| Neurocrine BioSciences, Inc. | 1 | $175 |
| Daiichi Sankyo Inc. | 1 | $135 |
| Vanda Pharmaceuticals Inc. | 1 | $123 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| KYOWA KIRIN, INC. | 1 | $122 |
| Abbott Laboratories | 1 | $121 |
| ViiV Healthcare Company | 1 | $120 |
Products named: REXULTI, INGREZZA, INJECTAFER, Epclusa, FANAPT, COBENFY, FREESTYLE LIBRE 3, APRETUDE.
Industry payments across NV — which companies pay providers there.
